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Neste trabalho, um sistema de cromatografia líquida de alta eficiência (HPLC) foi usado 
para desenvolver e validar um eficiente método para determinar quantitativamente aminoácidos 
envolvidos na desordem rara conhecida como cetonúria de aminoácidos de cadeia ramificada ou 
doença do xarope de bordo. As condições analíticas foram desenvolvidas para obter os perfis dos 
aminoácidos de L-valina, L-isoleucina e L-leucina, sabidamente alterados no plasma sanguíneo 
dos pacientes. Empregou-se HPLC provido de um detector com arranjo de diodo. Os analitos não 
possuem grupos cromóforos e, por isso, foram pré-derivatizados com o-ftalaldeído (OPA) para 
tornar possível sua detecção. A validação foi conduzida de acordo com as normas da Agência 
Nacional de Vigilância Sanitária (ANVISA) (RDC No. 27, de 17 de maio de 2012) e secção 
de validação de bioanalítica da United States Food and Drug Administration (U.S. FDA). Os 
resultados foram satisfatórios, apresentando alta sensibilidade, boa linearidade, precisão e exatidão, 
limite de detecção e quantificação, todos parâmetros estabelecidos para métodos bioanalíticos, 
demonstrando a aplicabilidade e baixo custo do método comparado com outras técnicas como 
espectrometria de massas. Para os três aminoácidos, L-valina, L-isoleucina e L-leucina, os limites 
de detecção encontrados foram: 1,61, 1,84 e 1,88 mmol L–1 e limites de quantificação 4,37, 6,13 
e 6,27 mmol L–1, respectivamente. 
A system of high performance liquid chromatography (HPLC) was used for the development 
and validation of efficient method for quantitative determination of three aminoacids involved in 
the inherited metabolic disease Branched-Chain Ketoaciduria (BCK), also called maple syrup urine 
disease. The analytical conditions were selected in order to obtain baseline separation profiles of the 
amino acids known to be altered in blood plasma of BCK patients, namely L-valine, L-isoleucine, 
and L-leucine. Most accurate data were obtained using HPLC/diode detector. As the analytes do 
not have chromophore groups, they were pre-derivatized with o-phthaldialdehyde (OPA), yielding 
an unsaturated adduct, making thus possible the detection of amino acids. The validation was 
conducted according to National Health Surveillance Agency (ANVISA) and Guidance for Industry 
(Bioanalytical Method Validation) United States Food and Drug Administration (U.S. FDA). 
The results were satisfactory, with high sensitivity, good linearity, precision and accuracy, limit 
of detection and quantification, all within the established parameters for bioanalytical methods, 
showing its applicability and low cost compared to other existing techniques such as sequential 
mass spectrometry. For the three amino acids, L-valine, L-isoleucine and L-leucine, the detection 
limits (LOD) found were: 1.61, 1.84 and 1.88 mmol L–1 and the quantification limits (LOQ) 4.37, 
6.13 and 6.27 mmol L–1, respectively.
Keywords: high performance liquid chromatography, maple syrup urine disease, isoleucinose, 
rare diseases, metabolism, inborn error, branched chain aminoacids, α-ketoacids
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Introduction
Hereditary metabolic diseases (HMD) or inborn errors 
of metabolism (IEM) are biochemical disorders genetically 
determined, involving processes of synthesis, storage or 
transport of molecules in the organism. In general, the main 
metabolic diseases associated with aminoacid metabolism 
are attributed to failure of a specific enzyme leading 
to accumulation or deficiency of intermediates in the 
corresponding metabolic pathway.1 In Brazil, the newborn 
screening public health program contemplates only a 
few inborn diseases such as phenylketonuria, congenital 
hypothyroidism, cystic fibrosis and hemoglobinophaties.2 
Other IEM are usually detected too late, when symptoms 
have been settled and damaged brain is often irreversible.3 
HMD are usually autosomal recessive, and it affects the 
population of about 1:5,000 live births.4 HMD is considered 
individually rare and most often leads to a late diagnosis 
with serious and irreparable consequences to the central 
nervous system. Importantly, early intervention in patients 
with IEM results in favorable clinical outcomes.5
Biochemical characteristics and laboratorial diagnosis 
of Branched-Chain Ketoaciduria (BCK) or maple syrup 
urine disease (MSUD) is considered a rare metabolic 
disorder with an incidence of approximately 1:200,000 
births. BCK is characterized by a deficiency in the 
multienzymecomplex of the ketoacids dehydrogenases 
(BCKAD) responsible for the metabolism of branched 
chain amino acids (BCAAs) L-leucine, L-isoleucine and 
L-valine. The consequence is the accumulation of BCAAs 
and its corresponding α-keto acids (A-α-CCR) in body 
fluids responsible for their toxicity to the central nervous 
system (CNS) and the sweet odor that coins the name of 
the disease - maple syrup urine disease.6 
Classic BCK, the most common and severe form, 
manifests between the fourth and seventh day of life with 
characteristic symptoms such as lethargy and poor milking 
followed by weight loss and neurological symptoms. Other 
symptoms include unwillingness to eat, convulsions, 
hiccups, hypothermia and coma, and ultimately death if 
the newborn is not treated.2 Early diagnosis is essential for 
prognosis, since rapid treatment may prevent neurological 
deterioration, characterized by reduced density of white 
matter hypomyelination/demyelination, atrophy and 
cerebral edema.
Twelve hours after birth, untreated neonates with classic 
BCK have a maple syrup urine odor and by 12-24 hours, 
elevated plasma concentrations of the BCAAs. Healthy 
individuals have reduced plasma concentrations of BCAAs 
during fasting, since the rate of oxidation of amino acids is 
higher than the rate of entry of protein in plasma. L-leucine 
(68-183 mmol L–1), L-isoleucine (31-105 mmol L–1), and 
L-valine (83-300 mmol L–1) are the reference values for 
plasma samples in children under 24 months. Because 
patients with untreated BCK are not able to oxidize BCAAs, 
they have increased plasma levels of these aminoacids.7 
Laboratory diagnostic tests reveal, in addition to increased 
blood, plasma or urine level of BCAAs and A-α-CCR, 
the presence of allo-isoleucine, a non-protein amino acid 
synthesized in vivo from isoleucine. Usually, children 
under 24 months have undetectable plasma levels of 
allo-isoleucine. Plasma concentrations of allo-isoleucine 
greater than 5 mmol L–1, alo-isoleucine/isoleucine ratio 
greater than 0.6, and leucine/alanine ratio above 0.5 
(reference values 0.1-0.5) are specific and sensitive markers 
of BCK. Another important feature is that the increased 
circulating BCAAs cause a decrease of other neutral 
amino acids such as tryptophan, tyrosine, methionine, and 
phenylalanine.8 The BCK treatment intends to normalize 
the blood levels of BCAAs by limiting the intake of the 
three essential aminoacids and provide adequate nutrition 
in order to maintain children growth and development.7 
Current treatment consists of restricting the dietary intake 
of BCAAs to the absolute minimum amount that is needed 
for growth.
Analytical methods for screening and diagnosis of BCK
Qualitative tests are important to provide clues regarding 
the type of IEM, although not conclusive for diagnostic. 
Qualitative urinary test with 2,4-dinitrophenylhydrazine 
(DNPH) can inform the presence of α-ketoacids in MSUD, 
but shows elevated L-leucine only at concentrations 
above 700 mmol L–1.9 Aminoacid separation techniques 
applied to biological fluids constitute important tools 
for diagnosing diseases caused by errors in metabolism. 
Liquid chromatography has been widely and succesfully 
used in this context because of its high precision, 
reproducibility and low cost in comparison with other 
methods. Chromatographic techniques coupled to tandem 
mass spectrometry (LC-MS/MS) although displaying 
high resolution, sensitivity and specificity have the 
disadvantage of high cost, frequently unaffordable for 
implementation in the public health service.10-12 On the 
other hand, high performance liquid chromatography 
with diode array detection (HPLC-DAD) offers a viable 
alternative for amino acid analysis due to its lower-cost, 
good reprodutibility, sensitivity and resolution.13 Here in 
we develop and validate a lower cost and high reliability 
HPLC-DAD analytical methodfor BCCAs determination 
in blood spot samples collected from normal and BKA 
patients.
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Experimental
Chemicals, stock solutions, standards and patient samples
Standards of the aminoacids L-valine, L-isoleucine 
and L-leucine (Sigma Aldrich, EUA) were used. Ortho-
phthaldehyde (OPA), 2-mercaptoethanol and Brij 35 were 
purchased from (Sigma Aldrich, EUA). The derivatization 
reagent used was prepared from 5 mg of OPA, 125 µL of 
methanol (Sigma Aldrich, USA), 1 mL of borate buffer 
0.4 mol L–1 (pH 9.5), 10 µL of 2-mercaptoethanol and 
1 µg (10 µL) Brij 35 obtained from a stock solution 
containing 0.1 mg mL–1. 2-mercaptoethanol was used to 
prevent OPA-aminoacid adduct to undergo hydrolysis. 
Brij 35 increases the detector response.
The eluents were prepared with methanol and 
tetrahydrofuran (HPLC grade) and 10 mmol L–1 sodium 
acetate buffer (pH 5.0). All chemicals used were from 
Sigma Aldrich, EUA. Ten mmol L–1 aminoacid solutions 
were prepareded in ultrapure water and stored at 4 °C 
for not more than four months. Water was purified in 
a Millipore Simplicity equipment and the card used 
to collect blood was from Schleicher & Schuell 903 
(S&S 903) (Germany).
Blood samples of healthy individual were collected with 
a tube containing EDTA as anticoagulant (VACUETTE™ 
Brasil). The samples were centrifuged at 1000 rpm for 
3 min, and the supernatant (plasma) was removed, diluted 
10 times in saline (0.9% NaCl) and filtered through a 
0.22 µm Millipore membrane. The samples were kept 
frozen at –4 °C until use.     
Blood collection card
Blood collection papers contain four circles (diameter, 
3.2 mm) to which blood drops were placed side by side 
until the entire circular areas were filled. Blood samples 
were reserved for drying at room temperature. After drying, 
the circles were cut out and the extraction was made with 
an adapted methodology14 using water, 1 mmol L–1 acetic 
acid and acetonitrile. To optimize the amino acid extraction 
efficiency, eluent combinations were tested by increasing 
10% the concentration of water in acetonitrile, starting 
from 29% to 89% water and maintaining the acetic acid 
concentration of 1%. 
i. 29% H2O; 1% acetic acid; 70% ACN
ii. 49% H2O; 1% acetic acid; 50% ACN
iii. 59% H2O; 1% acetic acid; 40% ACN
iv. 69% H2O; 1% acetic acid; 30% ACN
v. 79% H2O; 1% acetic acid; 20% ACN
vi. 89% H2O; 1% acetic acid; 10% ACN
The extraction of samples was performed by sonication 
for 20 min, which was followed by OPA derivatization 
before chromatographic analyses. This procedure was also 
employed for analyzing blood samples collected from three 
BCK patients aged five (two children), and seven years 
(one child). 
Chromatographic analyses
The HPLC system used comprises: PDA detector, 
Pump 600, automatic injector Autosampler all Accela 
(Thermo Scientific, USA), and a Phenosphere 5 microns 
C18, 80 Å column (Phenomenex, USA) Eluents A was 
10 mmol L–1 sodium acetate buffer (pH 5.0) in methanol and 
tetrahydrofuran at a ratio of 180:19:1and eluent B was 100% 
methanol. A gradient flux of 1 mL min–1 and an injection 
volume of 25 µL were used (Table 1). During a total time of 
21 min of analysis, the separation column was maintained at 
15 °C and absorption at 230 nm used to monitor the analyses. 
Method validation
The analytical method validation was conducted 
according to National Health Surveillance Agency 
(ANVISA) (RDC No. 27, of May 17, 2012) and the Guidance 
for Industry (Bioanalytical Method Validation)-FDA. The 
parameters evaluated were: specificity, linearity, detection 
limit, quantification limit, accuracy and precision.15 The 
study was approved by the institutional (UNIFESP) ethics 
committee, according to the protocol number 1545/10.
Specificity
The method specificity was assessed by analysis of 
plasma samples diluted ten-fold by the addition of standards 
Table 1. HPLC separation of a standards mixture of L-Leu, L-Ile, and L-Val, 
1 mmol L–1, volume injection: 25 µL. Mobile phase: solvent A: buffer (10 
mmol L–1 sodium acetate pH 5.0, in methanol and tetrahydrofuran at a ratio 
of 80:19:1) and solvent B: (HPLC grade methanol), with a flow rate of 
1.0 mL min–1. Excess OPA-containing derivatization solution (5:1, OPA/
Sample) was added to the blood extract to assure quantitative conversion 
of the amino acid to the corresponding OPA adduct    
time / min % A % B
0 50.0 50.0
15.0 30.0 70.0
20.0 30.0 70.0
21.0 0.0 100
22.0 100 0.0
23.0 0.0 100
24.0 100 0.0
25.0 50.0 50.0
45.0 50.0 50.0
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L-Leu, L-Ile and L-Val, and by checking interferences and 
retention time of the analytes.
Linearity
Calibration curves were constructed from five dilutions 
of each biomolecule from the same stock solutions, using 
the method of chi-square minimization (weighted least 
squares) and the blank. For the choice of concentrations 
the maximum limit of detection of aminoacid was 
observed, therefore the higher concentrations tested 
were lower than the maximum detection limit of the 
apparatus.
Detection and quantification limits
Detection limits were determined by the formula 
provided by the ANVISA resolution,15 which is based 
on the ratio of three times the baseline noise of the blank 
calibration curve of each biomolecule. The quantification 
limits were also determined using the formula given by 
ANVISA using the calibration curve obtained for each 
biomolecule.
Precision
The precision was determined by testing intra-
precision analyses (repeatability) at concentrations of 10, 
90 and 180 mmol L–1 and inter-precision analyses using 
90 mmol L–1 for the three analytes. Precision was expressed 
as coefficient of variation (CV%), accepted values being 
below 15%.
Accuracy
The accuracy was calculated as the percentage of 
recovery of the amount of L-Leu, L-Ile, and L-Val added 
to the plasma sample. Fifteen determinations were carried 
out, which include the linear range of the procedure, i.e., 
three concentrations (low, medium and high) with five 
replicates each of 2, 30 and 180 µmol L–1. Accuracy was 
expressed as the ratio between the average concentration 
determined experimentally and the corresponding 
theoretical concentration as percentage.
Standard stability
The aminoacid standard stabilities were studied within 
two monthsstorage at 4 °C, and evaluated by the variation 
of the peak chromatographic areas during validation. The 
stability of short duration (24 h) was also evaluated.
Results and Discussion
Chromatographic separation of the isomers L-Ile and 
L-Leu was afforded by the polarity differences caused by 
the different positions of methyl groups (Figure 1). Figure 1 
shows the isomer spatial representations, L-Leu having a 
larger volume than L-Ile, which can be evidenced by the 
total binding energies of the molecules. L-Leu has total 
energy = 151.149 and L-Ile 148.793 kJ mol–1 (calculated 
by Avogadro 4.7.2 software). This factor is responsible 
for the differences in L-Ile and L-Leu contact surface and 
contributes to the more effective L-Leu retention time in 
mobile phase and reversed phase chromatographic column. 
The retention times obtained for the aminoacid 
standards in the chromatographic conditions described 
were 12.73 ± 0.01, 15.86 ± 0.02 and 16.73 ± 0.02 min for 
L-Val, L-Ile and L-Leu, respectively (Figure 2).
Specificity
The aminoacids standard solution were injected 
independently onto the column in order to compare with 
blood plasma spiked with the same amino acids and the 
Figure 1. L-leucine (a) and L-isoleucine (b) spatial representations.
Figure 2. Chromatogram of a standard mixture of L-Val (1), L-Ile (2) 
and L-Leu (3) at 0.09 mmol L–1 spiked plasma sample obtained from a 
healthy adult volunteer. Column Phenosphere 5 µm, C18, 4.1 and 250 mm 
and 80 Å. Column temperature: 15 °C. Eluent A: sodium acetate buffer 
10 mmol L–1 pH 5.0; methanol and tetrahydrofuran 80:19:1. Eluent B: 
methanol. Injection volume: 25 µL. DAD λ = 230 nm.
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results were compared and showed no interference patterns 
in the respective retention times and peak resolution. 
Since OPA reacts only with primary amine groups, other 
compounds found in blood such as bilirrubin and lipids do 
not affect the HPLC traces.16
Linearity
The regression coefficient (r²) of the calibration 
curve was greater than 0.99 for all three metabolites. The 
aminoacid concentrations used were 2.0, 10.0, 30.0, 90.0 
and 180 mmol L–1, and the analyses were performed in 
quintuplicates. The straight line equation (y = bx + a) was 
determined through the study of linear regression: L-Val 
(1.43E8x – 687950.91), L-Leu (1.23E8x – 181002.98), and 
L-Ile (1.52E8x – 149073.31).
Sensitivity and accuracy
The detection limits (LOD) found for L-Val, L-Ile, 
and L-Leu, were 1.61, 1.84 and 1.88 mmol L–1 and the 
quantification limits (LOQ) 4.37, 6.13 and 6.27 mmol L–1, 
respectively. A HPLC method with UV detection validated 
by other authors16 found resulted in 0.43-1.91 mmol L–1 
LOD for all BCAAs. Student’s t test was used to check 
deviations from linearity of the calibration curve of the 
amino acids analyzed. As the tabulated T value found is 
less than the calculated T (Table 2), there is a correlation 
between the data and the calibration curve, with a 
confidence level of 95%. Therefore, we conclude that this 
methodology can detect and quantify amino acids levels 
much above that it is found in blood healthy individuals 
(Table 2).
The accuracy values for the 3 metabolites are listed in 
Table 3. All data obtained revealed intra-assay and inter-
assay precision values (CV%) falling below 15%.
Accuracy
Three aminoacid concentrations (2.0, 30 and 
180 mmol L–1) were analyzed in quintuplicate and the 
average recovery ranged from 91 to 108%. Another 
HPLC method with UV detection tested found similar 
results: 92-103%.17 Recently, other authors17 who used 
a HPLC method employing a 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate as the derivatizing reagent 
recovered from 96 to 105% amino acid.
Stability
No notable stability variations were observed for the 
three amino acids for either two months of storage at –4 °C 
or during a short term stability test at room temperature.
Analyses of BCK patient samples
Untreated BCK carriers, because are not able to oxidize 
BCAAs, have increased plasma levels of L-Leu, 500-5000 
(RV reference value: 68-183); L-Ile 200-1300 (RV 31-105); 
and L-Val: 500-1800 (RV: 83-300) (µmol L-1).7,18 Increased 
values were also found in blood spot samples of healthy 
individuals and BCK samples by Rashed et al.19 and in the 
present experiments (Table 4). The levels of L-Leu and L-Ile 
found here are reportedly compatible with the characteristic 
diagnostic values. Although patients A and B presented low 
levels of L-Leu, the sum of the two isomers shows compatible 
values with those of BCK patients. This fact can be attributed 
to variations in the individual patient’s metabolism or can 
result from undergoing treatment when the blood samples 
were withdrawn. Accordingly Rashed et al.,19 found similar 
results for BCK individuals using an electrospray MS/MS 
method. 
Identification and quantification of aminoacids in 
biological fluids have long been used for studying metabolic 
disorders. The photodiode array detector coupled to HPLC 
Table 2. Student’s t test applied to the amino acids analyzed
Aminoacid r² r n Tc Tta
L-valine 0.9996 0.9998 5 86.58 2.776
L-isoleucine 0.9992 0.9996 5 61.21 2.776
L-leucine 0.9999 0.9995 5 173.1 2.776
aValues found by the Student’s t distribution table.
Table 3. Intra-assay and inter-assay precision tests of amino acid analyses 
Concentration / 
(µmol L–1)
CV intra-assay / % CV inter-assay / %
L-valine
10 6.06 –
90 3.86 4.22
180 9.46 –
 L-isoleucine  
10 5.58 –
90 1.83 1.88
180 11.58 –
 L-leucine  
10 6.77 –
90 3.83 3.33
180 9.34 –
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allows fast, cheap and accurate analysis of amino acids 
because spans a wide range of the UV-Visible spectrum 
in a single chromatographic analysis. It makes possible a 
multivariate analysis with greater accuracy and reduced 
false positive results. The Brazilian Newborn Screening 
Public Health program contemplates just a few diseases, thus 
reflecting the lack of methods and technologies available 
in Brazilian public hospitals. In this context, the aim of 
the present study was the development and validation of a 
HPLC-DAD methodology for simultaneous quantification 
of the aminoacids that are characteristically altered in BCK: 
L-Leu, L-Ile, and L-Val. The method developed by this work 
uses sampling of blood drops, a single extraction phase, OPA 
derivatization and direct injection onto the HPLC system, 
which is quite applicable in laboratory scale.
The method is also suitable for routine clinical practice 
due to its high extraction efficiency, good reproducibility, 
and simultaneous quantification of three amino acids using a 
small volume of blood. This analysis is suitable for diagnostic 
and clinical monitoring of patients on therapeutic treatment. 
The linearity and the quantification limits obtained are 
satisfactory to detect individuals with BCK and distinguish 
them from healthy ones. The methodology performance was 
ratified through the linearity, accuracy and precision found in 
the present studies. Aminoacid standards were stable during 
the interval of time in which they were stocked. Similar blood 
sample collection and method validation have been employed 
for other metabolites that characterize several IEM.
The great advantage of this method is that it allows 
samples to be collected and transported by mail, important 
for populations that live in areas that do not have access to 
this type of diagnostic. The Brazilian Newborn Screening 
Public Health program contemplates just a few diseases, thus 
reflecting the lack of methods and technologies available in 
Brazilian public hospitals. In addition, it costs much less and 
may prevent the treatment of BCK carriers in the adulthood.
Conclusion
The development of the method described here proved 
to be consistent with the initial aims, both regarding the 
accuracy of results, facility of sample preparation, and 
interpretation of data. It was specifically designed to quantify 
BCCAs in BCK but can harness experimental conditions to 
detect other inherited aminoacid pathologies. The results 
validation of the bioanalytical method was satisfactory and 
baseline simultaneous separation of aminoacids. This was 
confirmed by the sensitivity, linear correlation, recovery, 
quantification and detection limits way below the levels 
obtained from healthy donors in the biological matrix. 
This method can be adopted by continental countries like 
Brazil, since samples can be mailed to a specialized center 
and the analyses carried out at a relatively low cost (under 
$ 10.00/patient), therefore much cheaper than methods 
using mass spectrometry.20
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